A Oseledchyk1, M M Leitao2,3, J Konner4,5, R E O'Cearbhaill4,5, D Zamarin4,5, Y Sonoda2,3, G J Gardner2,3, K Long Roche2,3, C A Aghajanian4,5, R N Grisham4,5, C L Brown2,3, A Snyder4,5, D S Chi2,3, R A Soslow6, N R Abu-Rustum2,3, O Zivanovic2,3. 1. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York. 2. Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York. 3. Department of OB/GYN, Weill Cornell Medical College, New York. 4. Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York. 5. Department of Medicine, Weill Cornell Medical College, New York. 6. Gynecologic Pathology, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database. PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to identify patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I EEOC or OCCC from 2000 to 2013. We sought to identify predictors of chemotherapy use and to assess the impact of chemotherapy on OS in these patients. OS was compared using the log-rank test and the Cox proportional hazards model. RESULTS: In all, 3552 patients with FIGO stage I EEOC and 1995 patients with stage I OCCC were identified. Of the 1600 patients (45%) with EEOC who underwent adjuvant chemotherapy, the 5-year OS rate was 90%, compared with 89% for those who did not undergo adjuvant chemotherapy (P = 0.807). Of the 1374 (69%) patients with OCCC who underwent adjuvant chemotherapy, the 5-year OS rate was 85%, compared with 83% (P = 0.439) for those who did not undergo adjuvant chemotherapy. Chemotherapy use was associated with younger age, higher substage, and more recent year of diagnosis for both the EEOC and OCCC groups. Only in the subgroup of patients with FIGO substage IC, grade 3 EEOC (n = 282) was chemotherapy associated with an improved 5-year OS-81% compared with 62% (P = 0.003) in untreated patients (HR: 0.583; 95% CI: 0.359-0.949; P = 0.030). In patients with OCCC, there was no significant effect of adjuvant chemotherapy on OS in any substage. CONCLUSIONS: Adjuvant chemotherapy was associated with improved OS only in patients with substage IC, grade 3 EEOC. In stage I OCCC, adjuvant chemotherapy was not associated with improved OS.
BACKGROUND: We sought to evaluate the impact of adjuvant chemotherapy on overall survival (OS) in patients with stage I endometrioid epithelial ovarian cancer (EEOC) or ovarian clear cell cancer (OCCC) using a national database. PATIENTS AND METHODS: The Surveillance, Epidemiology, and End Results database was used to identify patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I EEOC or OCCC from 2000 to 2013. We sought to identify predictors of chemotherapy use and to assess the impact of chemotherapy on OS in these patients. OS was compared using the log-rank test and the Cox proportional hazards model. RESULTS: In all, 3552 patients with FIGO stage I EEOC and 1995 patients with stage I OCCC were identified. Of the 1600 patients (45%) with EEOC who underwent adjuvant chemotherapy, the 5-year OS rate was 90%, compared with 89% for those who did not undergo adjuvant chemotherapy (P = 0.807). Of the 1374 (69%) patients with OCCC who underwent adjuvant chemotherapy, the 5-year OS rate was 85%, compared with 83% (P = 0.439) for those who did not undergo adjuvant chemotherapy. Chemotherapy use was associated with younger age, higher substage, and more recent year of diagnosis for both the EEOC and OCCC groups. Only in the subgroup of patients with FIGO substage IC, grade 3 EEOC (n = 282) was chemotherapy associated with an improved 5-year OS-81% compared with 62% (P = 0.003) in untreated patients (HR: 0.583; 95% CI: 0.359-0.949; P = 0.030). In patients with OCCC, there was no significant effect of adjuvant chemotherapy on OS in any substage. CONCLUSIONS: Adjuvant chemotherapy was associated with improved OS only in patients with substage IC, grade 3 EEOC. In stage I OCCC, adjuvant chemotherapy was not associated with improved OS.
Authors: Th E M Crijnen; M L G Janssen-Heijnen; H Gelderblom; J Morreau; M A Nooij; G G Kenter; H F A Vasen Journal: Fam Cancer Date: 2005 Impact factor: 2.375
Authors: Michael Herman Chui; Paul Ryan; Jordan Radigan; Sarah E Ferguson; Aaron Pollett; Melyssa Aronson; Kara Semotiuk; Spring Holter; Keiyan Sy; Janice S Kwon; Anita Soma; Naveena Singh; Steven Gallinger; Patricia Shaw; Jocelyne Arseneau; William D Foulkes; C Blake Gilks; Blaise A Clarke Journal: Am J Surg Pathol Date: 2014-09 Impact factor: 6.394
Authors: Emily N Prendergast; Marie Holzapfel; Jennifer J Mueller; Mario M Leitao; Camille C Gunderson; Kathleen N Moore; Britt K Erickson; Charles A Leath; Elena S Diaz Moore; Joshua G Cohen; Christine S Walsh Journal: Gynecol Oncol Date: 2016-12-12 Impact factor: 5.482
Authors: Aalok Kumar; Nhu Le; Anna V Tinker; Jennifer L Santos; Christina Parsons; Paul J Hoskins Journal: Int J Gynecol Cancer Date: 2014-10 Impact factor: 3.437
Authors: P Watson; R Bützow; H T Lynch; J P Mecklin; H J Järvinen; H F Vasen; L Madlensky; P Fidalgo; I Bernstein Journal: Gynecol Oncol Date: 2001-08 Impact factor: 5.482
Authors: John K Chan; Deanna Teoh; Jessica M Hu; Jacob Y Shin; Kathryn Osann; Daniel S Kapp Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482
Authors: M Takano; Y Kikuchi; N Yaegashi; K Kuzuya; M Ueki; H Tsuda; M Suzuki; J Kigawa; S Takeuchi; H Tsuda; T Moriya; T Sugiyama Journal: Br J Cancer Date: 2006-05-22 Impact factor: 7.640
Authors: Koji Matsuo; Yongmei Huang; Oliver Zivanovic; Muneaki Shimada; Hiroko Machida; Brendan H Grubbs; Lynda D Roman; Jason D Wright Journal: Gynecol Oncol Date: 2019-07-04 Impact factor: 5.482
Authors: Jason A Konner; Dmitriy Zamarin; Tiffany Y Sia; Beryl Manning-Geist; Sushmita Gordhandas; Rajmohan Murali; Antonio Marra; Ying L Liu; Claire F Friedman; Travis J Hollmann; Oliver Zivanovic; Dennis S Chi; Britta Weigelt Journal: Int J Gynecol Cancer Date: 2022-08-01 Impact factor: 4.661
Authors: Hee Yeon Lee; Ji Hyung Hong; Jae Ho Byun; Hee-Jun Kim; Sun Kyung Baek; Jin Young Kim; Ki Hyang Kim; Jina Yun; Jung A Kim; Kwonoh Park; Hyo Jin Lee; Jung Lim Lee; Young-Woong Won; Il Hwan Kim; Woo Kyun Bae; Kyong Hwa Park; Der-Sheng Sun; Suee Lee; Min-Young Lee; Guk Jin Lee; Sook Hee Hong; Yun Hwa Jung; Ho Jung An Journal: Cancer Res Treat Date: 2019-07-12 Impact factor: 4.679
Authors: Paulina Cybulska; Jill Tseng; Qin C Zhou; Alexia Iasonos; Deborah F Delair; Jennifer J Mueller; Kara C Long Roche; Nadeem R Abu-Rustum; Mario M Leitao Journal: J Surg Oncol Date: 2021-07-16 Impact factor: 2.885